Over half of patients newly diagnosed with multiple myeloma are not eligible for transplant. Listen as Dr. Yee provides treatment planning options to patients who are ineligible for transplant.
Find the CANCER BUZZ podcast on Apple Podcasts, Spotify, or wherever you get your podcasts!
Multiple myeloma refers to blood cancer found within the plasma cells of bone marrow. It is a rare cancer, affecting less than one percent of the U.S. population. Currently, there is no cure for multiple myeloma, but there are treatment options that can help people live longer, healthier lives. Stem cell transplant is a standard of care for eligible patients. However, over half of patients newly diagnosed with multiple myeloma are not eligible for transplant due to age or other major health problems, such as heart, lung, liver, or kidney disease. And studies have shown people who are ineligible for transplant have a lower survival rate.
Listen as Dr. Yee provides treatment planning options available to patients who are ineligible for transplant.
Guest
Andrew Yee, MD
Clinical Director
Center for Multiple Myeloma at Massachusetts General Hospital
Assistant Professor of Medicine
Harvard Medical School, Boston, MA
“Overtime these patients can experience significant improvements in quality of life…they can go back to their normal routine. Ultimately, there needs to be a shared decision between the patient and the care team in terms of what their goals and priorities are.” – Andrew Yee, MD
This podcast was generously supported by Janssen Oncology. This podcast was developed through a collaboration between The Association of Community Cancer Centers and The Leukemia & Lymphoma Society.
Resources:
The views and opinions expressed herein are those of the author(s)/faculty member(s) and do not reflect the official policy or position of their employer(s) or the Association of Cancer Care Centers.
Understanding both the benefits to be had from offering BsAb therapy to its community and the scope of this undertaking, Vanderbilt-Ingram Cancer Center took a novel approach with its APP-led BsAb step-up dosing clinic, which won the program a 2026 ACCC Innovator Award.
